ArticleAntimicrobial agents and chemotherapy2018
Pharmacokinetics and Comprehensive Analysis of the Tissue Distribution of Eravacycline in Rabbits.
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Eravacycline as a Novel Option for Treating Multidrug-Resistant Gram-Negative and Gram-Positive Bacterial Infections: A Narrative Review.Journal of clinical medicine · 2026Review
- In vitro and in vivo activity of eravacycline against Mycobacterium abscessus.BMC microbiology · 2026Article
- Managing skin infections in burn patients: principles and pitfalls.Current opinion in infectious diseases · 2026Review
- Intrathecal combined with intravenous eravacycline for the treatment of multisite carbapenem-resistantFrontiers in medicine · 2026Article
- Incidence and characteristics of eravacycline-associated increase in serum bilirubin levels: a retrospective study.Frontiers in pharmacology · 2026Article
- NDM-ProducingFrontiers in medicine · 2026Article
- Review
- New Antibiotics for the Treatment of Nosocomial Central Nervous System Infections.Antibiotics (Basel, Switzerland) · 2024Review
- In vitro Antimicrobial Activity and Dose Optimization of Eravacycline and Other Tetracycline Derivatives Against Levofloxacin-Non-Susceptible and/or Trimethoprim-Sulfamethoxazole-ResistantInfection and drug resistance · 2023Article
- Inadequate Cerebrospinal Fluid Concentrations of Available Salvage Agents Further Impedes the Optimal Treatment of Multidrug-ResistantInfectious disease reports · 2021Article
- Clinical Pharmacokinetics and Pharmacodynamics of Eravacycline.Clinical pharmacokinetics · 2019Review
- Mass Balance and Drug Interaction Potential of Intravenous Eravacycline Administered to Healthy Subjects.Antimicrobial agents and chemotherapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eravacycline (7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline or TP-434) is a novel, fully synthetic broad-spectrum fluorocycline with potent activity against Gram-positive bacteria, anaerobes, and multidrug-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.